AN2 Therapeutics

AN2 Therapeutics

Pharmaceuticals
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

$187.8M

Market Cap • 11/18/2026

2017

(9 years)

Founded

2022

(4 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2,5

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2

EPS

—

Market Cap

Market Cap

187,8M

EV

123,4M

EV/Revenue

—

EV/EBITDA

-3,3

EV/EBIT

-3,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-24,3%

Total Yield

-24,3%

Payout

0%

Retained Earnings

-267,1M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0%

% Goodwill

0%

ROE

—

ROIC

—

Leverage

N.D./EBITDA

1,7

Debt/Equity

0%

Current Ratio

10,5

Quick Ratio

10,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium